Marianne de Backer
Chief Executive Officer at VIR BIOTECHNOLOGY, INC.
Net worth: 7 M $ as of 2024-03-30
Marianne de Backer active positions
| Companies | Position | Start | End |
|---|---|---|---|
| VIR BIOTECHNOLOGY, INC. | Director/Board Member | 2023-04-02 | - |
| Chief Executive Officer | 2023-04-02 | - | |
| Corporate Officer/Principal | - | 2023-04-02 | |
EcoHealth Alliance, Inc.
 EcoHealth Alliance, Inc. Miscellaneous Commercial ServicesCommercial Services EcoHealth Alliance, Inc. operates a not for profit organization. It protects the health of people, animals, and the environment. Its programs include rift valley fever, predict, health and policy initiatives, monitoring the deadly Nipah virus, emerging disease hotspots, project deep forest, ecohealthy pets, global wildlife trade, and economics of emerging infectious diseases. The company is headquartered in New York, NY. | Director/Board Member | - | - |
| Gladstone Foundation (CA) | Director/Board Member | - | - |
Vividion Therapeutics, Inc.
 Vividion Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Vividion Therapeutics, Inc. operates as a biotechnology company. The company focuses on developing innovative therapeutics that treat major unmet clinical needs using the first platform for proteome wide drug and target discovery. It's proprietary chemoproteomic platform technology addresses the key limitations of conventional screening techniques and allows the discovery of previously unknown, or cryptic, functional pockets on the surface of proteins and identification of small molecules that selectively bind to those targets. The company was founded by Benjamin F. Cravatt, Phil S. Baran, Jin-Quan Yu and John K. Clarke on December 24, 2013 and is headquartered in San Diego, CA. | Director/Board Member | - | - |
Agenovir Corp.
 Agenovir Corp. Pharmaceuticals: MajorHealth Technology Agenovir Corp. provides research and developing novel antiviral therapeutics for diseases. The company was founded by Bruce Hironaka and Stephen R. Quake and is headquartered in San Francisco, CA. | Chief Executive Officer | - | - |
| President | - | - |
Career history of Marianne de Backer
Former positions of Marianne de Backer
| Companies | Position | Start | End |
|---|---|---|---|
| KRONOS BIO, INC. | Director/Board Member | 2021-01-24 | 2023-06-22 |
| Independent Dir/Board Member | 2021-01-24 | 2023-06-22 | |
| ARROWHEAD PHARMACEUTICALS, INC. | Director/Board Member | 2019-12-11 | 2023-04-01 |
| Independent Dir/Board Member | 2019-12-11 | 2023-04-01 | |
| BAYER AG | Corporate Officer/Principal | 2019-09-06 | 2023-02-28 |
| JOHNSON & JOHNSON | Corporate Officer/Principal | 1990-12-31 | 2018-12-31 |
| ░░░░░░░░ ░░░░░░░░░░░░ ░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - | - |
| ░░░░░░░░░ ░░░░░░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - | - |
Training of Marianne de Backer
| Ghent University | Doctorate Degree |
| Vrije Universiteit Brussel | Graduate Degree |
| Rotterdam School of Management | Masters Business Admin |
Statistics
International
| United States | 11 |
| Belgium | 3 |
| Germany | 2 |
Operational
| Director/Board Member | 8 |
| Corporate Officer/Principal | 3 |
| Graduate Degree | 2 |
Sectoral
| Health Technology | 8 |
| Consumer Services | 4 |
| Commercial Services | 4 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 5 |
|---|---|
| JOHNSON & JOHNSON | Health Technology |
| ARROWHEAD PHARMACEUTICALS, INC. | Health Technology |
| BAYER AG | Health Technology |
| VIR BIOTECHNOLOGY, INC. | Health Technology |
| KRONOS BIO, INC. | Health Technology |
| Private companies | 6 |
|---|---|
Asklepios BioPharmaceutical, Inc.
 Asklepios BioPharmaceutical, Inc. BiotechnologyHealth Technology Asklepios BioPharmaceutical, Inc. operates as a gene therapy-based company. It engages in capsid development, scaled manufacturing, and a portfolio of therapeutic programs. The company was founded by Richard Jude Samulski, Xiao Xiao, and Sheila A. Mikhail in 2001 and is headquartered in Durham, NC. | Health Technology |
EcoHealth Alliance, Inc.
EcoHealth Alliance, Inc. Miscellaneous Commercial ServicesCommercial Services EcoHealth Alliance, Inc. operates a not for profit organization. It protects the health of people, animals, and the environment. Its programs include rift valley fever, predict, health and policy initiatives, monitoring the deadly Nipah virus, emerging disease hotspots, project deep forest, ecohealthy pets, global wildlife trade, and economics of emerging infectious diseases. The company is headquartered in New York, NY. | Commercial Services |
| Gladstone Foundation (CA) | |
Vividion Therapeutics, Inc.
Vividion Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Vividion Therapeutics, Inc. operates as a biotechnology company. The company focuses on developing innovative therapeutics that treat major unmet clinical needs using the first platform for proteome wide drug and target discovery. It's proprietary chemoproteomic platform technology addresses the key limitations of conventional screening techniques and allows the discovery of previously unknown, or cryptic, functional pockets on the surface of proteins and identification of small molecules that selectively bind to those targets. The company was founded by Benjamin F. Cravatt, Phil S. Baran, Jin-Quan Yu and John K. Clarke on December 24, 2013 and is headquartered in San Diego, CA. | Commercial Services |
Agenovir Corp.
Agenovir Corp. Pharmaceuticals: MajorHealth Technology Agenovir Corp. provides research and developing novel antiviral therapeutics for diseases. The company was founded by Bruce Hironaka and Stephen R. Quake and is headquartered in San Francisco, CA. | Health Technology |
BlueRock Therapeutics LP
 BlueRock Therapeutics LP Miscellaneous Commercial ServicesCommercial Services Part of Bayer AG, BlueRock Therapeutics LP is a clinical stage cell therapy company based in Cambridge, MA. The private company is focused on creating cellular medicines to reverse devastating diseases such as neurological, cardiovascular, immunological, and ophthalmic diseases. BlueRock Therapeutics's lead clinical program, Bemdaneprocel, is in phase I clinical trials for Parkinson's disease. In late 2019, BlueRock became a wholly owned, independently operated subsidiary of Bayer AG as a cornerstone of its newly formed cell & gene therapy platform. The company's culture is defined by the courage to persist regardless of the challenge, the urgency to transform medicine and deliver hope, integrity guided by mission, and community-mindedness with the understanding that they are all part of something bigger than themselves. The company was founded in 2016 as a joint venture of Versant Ventures and Leaps by Bayer, the impact investing arm of Bayer AG that invests in paradigm-shifting breakthrough innovation. | Commercial Services |
- Stock Market
- Insiders
- Marianne de Backer
- Experience
